secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vincerx Pharma, Inc. (—)
CIK:        0001796129
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001193125-24-082002
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vincerx Pharma FY2023 net loss $40.2M; cash $12.8M, runway into early Q3 2024
-----------------------------------------------------------------------------

- Net loss for FY2023: $40.2M ($1.89/share) vs $63.0M ($3.00/share) in FY2022; Q4 2023 loss $4.9M ($0.23/share).
- Cash and equivalents $12.8M as of Dec 31, 2023, down from $52.5M year-end 2022; expects runway into early Q3 2024.
- R&D expenses fell to $29.0M in FY2023 from $49.8M in FY2022; G&A down to $13.6M from $18.9M.
- Pipeline: VIP236 Phase 1 dose-escalation ongoing with 20 patients; VIP943 Phase 1 enrolling third cohort (9 patients dosed).
- Enitociclib (CDK9 inhibitor) showed partial responses in PTCL and DLBCL combination studies with NIH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/0001193125-24-082002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/d743689d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer